Pancreatic CancerMMTIPSNCT06938906
Multimodal Therapy Impact on Pancreatic Cancer Survival
An observational study of Pancreatic Cancer and Neoadjuvant Chemotherapy, run by National Cheng Kung University at 1 site in Taiwan.
Trial summary
The goal of this retrospective cohort study is to analyze change of treatment strategies affect the survival outcomes in patients of pancreatic cancer who received curative-intent treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cancer, Neoadjuvant Chemotherapy, Pancreatectomy
- How many people
- 405 participants
- Where
- 1 siteTaiwan
- Study dates
- 3 Jan 2011to 30 Apr 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with pancreatic cancer who lived in southern Taiwan.
Who may be able to join
- Pancreatic adenocarcinoma
- Received curative surgery
Who cannot join
- Other subtypes of pancreatic cancer including acinar cell carcinoma, mucinous carcinoma, undifferentiated carcinoma and intraductal papillary mucinous neoplasm with associated adenocarcinoma
- Cases with palliative or R2 resection were also excluded from the analysis.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Survival Outcome Analysis on the Strategy Shift Integrating a Multimodal Therapy of Neoadjuvant Chemotherapy and Extended Pancreatectomy in Pancreatic Cancer: A Clinical Study From a Retrospective Cohort in a Single Institute
The goal of this retrospective cohort study is to analyze change of treatment strategies affect the survival outcomes in patients of pancreatic cancer who received curative-intent treatment. The main question it aims to answer is:
Hypothesis: Change of treatment strategies involving increased utility of neoadjuvant chemotherapy and aggressive surgical approaches of extended pancreatectomy improved the overall and progression free survival in the patients with pancreatic cancer.
Participants received curative treatment for pancreatic cancer.
Read the detailed description
This study is to analyze the change of treatment strategies and shift of the paradigm over time in a single center. Researchers plan to see the impact of the evolvement to the survival outcomes in pancreatic cancer.
- Conditions
- Pancreatic Cancer, Neoadjuvant Chemotherapy, Pancreatectomy
- Keywords
- pancreatic cancer, neoadjuvant chemotherapy, extended pancreatectomy, multimodal therapy, paradigm shift, survival outcomes
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group A | The patient of pancreatic cancer, who began to have treatment in the period between 2011 to 2017. | |
| Group B | The patient of pancreatic cancer, who began to have treatment in the period between 2018 to 2022. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival and Progression-free survival
Overall survival was calculated from the first treatment day of the disease to the day of mortality. Progression-free survival was calculated from the first treatment day of the disease to the day of proression or recurrece of pancreatic cancer.
Measured: From enrollment to two years after the end of treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2025
- Study start3 Jan 2011
- Primary completion30 Apr 2025 (estimated)
- Study completion30 Apr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 405 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Cheng Kung University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ting-Kai Liao, National Cheng Kung University
- Investigators
- Yan-Shen Shan, MD., PhD., Study chair, Department of Surgery, National Cheng Kung University HospitalTing-Kai Liao, MD., Study director, National Cheng-Kung University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06938906
- Sponsor's protocol ID
- NCKUH-11405009
- Acronym
- MMTIPS
- Status last verified
- Apr 2025
- First submitted
- 14 Apr 2025
- Last updated
- 24 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Survival Outcome Analysis on the Strategy Shift Integrating a Multimodal Therapy of Neoadjuvant Chemotherapy and Extended Pancreatectomy in Pancreatic Cancer: A Clinical Study From a Retrospective Cohort in a Single Institute
- ClinicalTrials.gov ID
- NCT06938906
- Acronym / sponsor ID
- MMTIPS / NCKUH-11405009
- Conditions
- Pancreatic Cancer, Neoadjuvant Chemotherapy, Pancreatectomy
- Keywords
- pancreatic cancer, neoadjuvant chemotherapy, extended pancreatectomy, multimodal therapy, paradigm shift, survival outcomes
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 405 participants (actual)
- Lead sponsor
- National Cheng Kung UniversityUniversity, hospital or other
- Study start
- 3 Jan 2011 (actual)
- Primary completion
- 30 Apr 2025 (estimated)
- Study completion
- 30 Apr 2025 (estimated)
- First posted
- 22 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this retrospective cohort study is to analyze change of treatment strategies affect the survival outcomes in patients of pancreatic cancer who received curative-intent treatment. The main question it aims to answer is:
Hypothesis: Change of treatment strategies involving increased utility of neoadjuvant chemotherapy and aggressive surgical approaches of extended pancreatectomy improved the overall and progression free survival in the patients with pancreatic cancer.
Participants received curative treatment for pancreatic cancer.
Detailed description
This study is to analyze the change of treatment strategies and shift of the paradigm over time in a single center. Researchers plan to see the impact of the evolvement to the survival outcomes in pancreatic cancer.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A | – | –The patient of pancreatic cancer, who began to have treatment in the period between 2011 to 2017. |
| Group B | – | –The patient of pancreatic cancer, who began to have treatment in the period between 2018 to 2022. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with pancreatic cancer who lived in southern Taiwan.
Key inclusion criteria (2 listed)
- Pancreatic adenocarcinoma
- Received curative surgery
Key exclusion criteria (2 listed)
- Other subtypes of pancreatic cancer including acinar cell carcinoma, mucinous carcinoma, undifferentiated carcinoma and intraductal papillary mucinous neoplasm with associated adenocarcinoma
- Cases with palliative or R2 resection were also excluded from the analysis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall survival and Progression-free survival
Time frame: From enrollment to two years after the end of treatment
Overall survival was calculated from the first treatment day of the disease to the day of mortality. Progression-free survival was calculated from the first treatment day of the disease to the day of proression or recurrece of pancreatic cancer.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yan-Shen Shan, MD., PhD. study chair
Department of Surgery, National Cheng Kung University Hospital
Ting-Kai Liao, MD. study director
National Cheng-Kung University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Cancer and Neoadjuvant Chemotherapy, run by National Cheng Kung University at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 24 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival and Progression-free survival (time frame: From enrollment to two years after the end of treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2025.